Drug Database
Back to search

United States· US:70710-1626_5364926a-5a07-440a-a27e-1435a9e4d4f9

balsalazide disodium

A balsalazide product containing balsalazide disodium, registered in United States by Zydus Pharmaceuticals (USA) Inc.. The same ATC class is registered in 6 of our 19 countries.

ATC A07EC04US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedbalsalazide disodiumATCA07EC04REGISTER NO.US:70710-1626_5364926…PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about balsalazide disodiumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Balsalazide is registered in 6 of 19 countries.

Countries holding a registration under ATC A07EC04 (balsalazide), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 4 of them publish a price we can compare per daily dose
Search balsalazide products by name

Balsalazide · ATC A07EC04

6 / 19 countries

  • Denmark
  • Icelandprice
  • Italyprice
  • Norwayprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
BALSALAZIDE DISODIUM
Manufacturer
Zydus Pharmaceuticals (USA) Inc.
Country
United States (US)
ATC code
A07EC04
ATC class
Balsalazide
Defined daily dose
6.75 g, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 2

  • ndc11
    7071016261
    280 CAPSULE in 1 BOTTLE (70710-1626-1)
  • ndc11
    70710-1626-1

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

212 interactions on record for balsalazide.

Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check balsalazide against other medicinesHow interaction checks work

Balsalazide · interactions on record

212 records

  • 15 severe
  • 146 moderate
  • 51 info

Most severe, free to view

  • CidofovirJ05AB12severe
  • Humane Immunglobuline, unspezifisch, extravaskulärJ06BA01severe
  • Humane Immunglobuline, unspezifisch, intravaskulärJ06BA02severe
  • SirolimusL01EG04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Balsalazide in 5 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All balsalazide products

Authorised across Europe · EMA

The same active substance is authorised in 6 EEA countries. Names it is sold under:

  • Denmark · Premid
  • United Kingdom (Northern Ireland) · Colazide
  • Iceland · Colazid
  • Italy · Balzide
  • Norway · Colazid
  • Sweden · Colazid

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/98ad9fe5-4b67-498c-9674-5db1ed9f70f2
GET /v1/drugs/98ad9fe5-4b67-498c-9674-5db1ed9f70f2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "750",
  "substance": "BALSALAZIDE DISODIUM",
  "productndc": "70710-1626",
  "dosage_form": "CAPSULE",
  "dea_schedule": null,
  "strength_unit": "mg/1",
  "application_number": "ANDA217592",
  "marketing_category": "ANDA"
}
API referenceMCP serverPlans

See everything about balsalazide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console